NASA’s Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observations (CALIPSO) and CloudSat satellites are set to launch aboard a Boeing Delta II rocket at 3:02 a.m. PDT on Friday, April 21, from ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Century Therapeutics, Inc. is conducting ...
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% ...
Hosted on MSN
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs.
Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares. Century is conducting the Phase I CALiPSO-1 study of CNTY-101 ...
CALiPSO-1 will assess CNTY-101 in patients who have been exposed to two or more standard immunosuppressive therapies. The trial is on track to be initiated in the first half of 2024 with preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results